Do Poor Prognostic Factors in Rheumatoid Arthritis Affect Treatment Choices and Outcomes? Analysis of a US Rheumatoid Arthritis Registry
Department of Medicine, Division of Rheumatology
Clinical Epidemiology | Epidemiology | Immune System Diseases | Musculoskeletal Diseases | Rheumatology | Therapeutics
OBJECTIVE: To characterize patients with rheumatoid arthritis (RA) by number of poor prognostic factors (PPF: functional limitation, extraarticular disease, seropositivity, erosions) and evaluate treatment acceleration, clinical outcomes, and work status over 12 months by number of PPF.
METHODS: Using the Corrona RA registry (January 2005-December 2015), biologic-naive patients with diagnosed RA having 12-month (+/- 3 mos) followup were identified and categorized by PPF (0-1, 2, > /= 3). Changes in medication, Clinical Disease Activity Index (CDAI), and work status (baseline-12 mos) were evaluated using linear and logistic regression models.
RESULTS: There were 3458 patients who met the selection criteria: 1489 (43.1%), 1214 (35.1%), and 755 (21.8%) had 0-1, 2, or > /= 3 PPF, respectively. At baseline, patients with > /= 3 PPF were older, and had longer RA duration and higher CDAI versus those with 0-1 PPF. In 0-1, 2, and > /= 3 PPF groups, respectively, 20.9%, 23.2%, and 26.5% of patients received > /= 1 biologic (p = 0.011). Biologic/targeted synthetic disease-modifying antirheumatic drug (tsDMARD) use was similar in patients with/without PPF (p = 0.57). After adjusting for baseline CDAI, mean (standard error) change in CDAI was -4.95 (0.24), -4.53 (0.27), and -2.52 (0.34) for 0-1, 2, and > /= 3 PPF groups, respectively. More patients were working at baseline but not at 12-month followup in 2 (13.9%) and > /= 3 (12.5%) versus 0-1 (7.3%) PPF group.
CONCLUSION: Despite high disease activity and worse clinical outcomes, number of PPF did not significantly predict biologic/tsDMARD use. This may warrant reconsideration of the importance of PPF in treat-to-target approaches.
COHORT STUDIES, PATIENT OUTCOME ASSESSMENT, PROGNOSIS, RHEUMATOID ARTHRITIS
Rights and Permissions
© 2018. Free online via JRheum Full Release option
DOI of Published Version
J Rheumatol. 2018 Oct;45(10):1353-1360. doi: 10.3899/jrheum.171050. Epub 2018 Jul 1. Link to article on publisher's site
The Journal of rheumatology
Alemao E, Litman HJ, Connolly SE, Kelly S, Hua W, Rosenblatt L, Rebello S, Kremer JM, Harrold LR. (2018). Do Poor Prognostic Factors in Rheumatoid Arthritis Affect Treatment Choices and Outcomes? Analysis of a US Rheumatoid Arthritis Registry. Open Access Articles. https://doi.org/10.3899/jrheum.171050. Retrieved from https://escholarship.umassmed.edu/oapubs/3641